tradingkey.logo

BRIEF-Merck Outlook 2025 Adj EPS $8.88 - $9.03 Vs IBES Estimate $9.02

ReutersFeb 4, 2025 11:39 AM

- Merck & Co Inc MRK.N:

  • Q4 ADJUSTED EPS $1.72 VERSUS IBES ESTIMATE $1.62

  • OUTLOOK 2025 ADJUSTED EPS $8.88 - $9.03 VERSUS IBES ESTIMATE $9.02

  • OUTLOOK 2025 WORLDWIDE SALES $64.1 BILLION - $65.6 BILLION VERSUS IBES ESTIMATE $67.31 BILLION

  • 2025 SALES RANGE REFLECTS DECISION TO TEMPORARILY PAUSE SHIPMENTS OF GARDASIL/GARDASIL 9 TO CHINA FROM FEB THROUGH AT LEAST MID-YEAR

  • Q4 WORLDWIDE SALES $15.62 BILLION VERSUS IBES ESTIMATE $15.49 BILLION

  • Q4 KEYTRUDA SALES $7.84 BILLION

  • Q4 GARDASIL/GARDASIL 9 SALES $1.55 BILLION, DOWN 17% DUE TO LOWER DEMAND IN CHINA

Source text: [ID:]

Further company coverage: MRK.N

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI